Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory. Occupational Safety and Health the depository institution may continue The information collected on the FR (NIOSH) of the Centers for Disease to report that account as a ‘‘savings 2886b is generally not considered Control and Prevention (CDC), in the deposit’’ or may instead choose to report confidential, but certain data may be Department of Health and Human that account as a ‘‘transaction account.’’ exempt from disclosure pursuant to Services announces that the following draft documents are available for public (3) Report title: Consolidated Report exemptions (b)(4) and (b)(7)(C) of FOIA, comment: (1) NIOSH Procedures for of Condition and Income for Edge and (5 U.S.C. 552(b)(4) and (b)(7)(C)). The Developing the NIOSH List of Agreement Corporations. information exempt from disclosure Agency form number: FR 2886b. Hazardous Drugs in Healthcare Settings OMB control number: 7100–0086. pursuant to (b)(4) consists of (Procedures); (2) NIOSH List of Applicable date: May 1, 2020. information provided on Schedule RC– Hazardous Drugs in Healthcare Settings, Frequency: Quarterly and annually. M (with the exception for item 3) and 2020 (List), including those drugs Respondents: Banking Edge and on Schedule RC–V, both of which proposed for placement on the 2020 agreement corporations and investment pertain to claims on and liabilities to List, and (3) Managing Hazardous Drug (nonbanking) Edge and agreement related organizations. The information Exposures: Information for Healthcare corporations. exempt from disclosure pursuant to Settings. Estimated number of respondents: exemption (b)(7)(C) is information DATES: Comments must be received by Banking Edge and agreement provided in the Patriot Act Contact June 30, 2020. corporations (quarterly): 9; banking Information section of the reporting ADDRESSES: Edge and agreement corporations form. Comments may be (annually): 1; investment Edge and submitted, identified by docket numbers agreement corporations (quarterly): 21; Current actions: The Board has CDC–2020–0046 and NIOSH–233–C, by investment Edge and agreement temporarily revised the instructions to either of the following two methods: corporations (annually): 7. the FR 2886b to update the definition of • Federal eRulemaking Portal: Estimated average hours per response: ‘‘savings deposits’’ in accordance with www.regulations.gov Follow the Banking Edge and agreement the amendments to Regulation D in the instructions for submitting comments. corporations (quarterly): 15.77 hours; interim final rule published on April 28, • Mail: NIOSH Docket Office, Robert banking Edge and agreement 2020 (85 FR 23445). Specifically, the A. Taft Laboratories, MS–C34, 1090 corporations (annually): 15.87; Board has temporarily revised the Tusculum Avenue, Cincinnati, OH investment Edge and agreement instructions on Schedule RC–E to 45226–1998. corporations (quarterly): 11.81; remove the transfer and withdrawal Instructions: All information received investment Edge and agreement limit from the definition of a savings in response to this notice must include corporations (annually): 10.82. deposit. Please note that this revision the agency name and the docket Estimated annual burden hours: does not require any changes to the form numbers (CDC–2020–0046; NIOSH– Banking Edge and agreement itself. As a result of the revision, if a 233–C). All relevant comments received corporations (quarterly): 568; banking depository institution chooses to will be posted without change to Edge and agreement corporations suspend enforcement of the six transfer www.regulations.gov, including any (annually): 16; investment Edge and limit on a ‘‘savings deposit,’’ the personal information provided. agreement corporations (quarterly): 992; depository institution may continue to FOR FURTHER INFORMATION CONTACT: investment Edge and agreement report that account as a ‘‘savings Barbara MacKenzie, NIOSH, Robert A. corporations (annually): 76. deposit’’ or may instead choose to report Taft Laboratories, 1090 Tusculum General description of report: The FR that account as a ‘‘transaction account.’’ Avenue, MS–C26, Cincinnati, OH 2886b reporting form is filed quarterly 45226, telephone (513) 533–8132 (not a and annually by banking Edge and Board of Governors of the Federal Reserve toll free number), email:bmackenzie@ agreement corporations and investment System, April 28, 2020. cdc.gov. (nonbanking) Edge and agreement Michele Taylor Fennell, SUPPLEMENTARY INFORMATION: corporations (collectively, Edges or Edge Assistant Secretary of the Board. corporations). The mandatory FR 2886b [FR Doc. 2020–09342 Filed 4–30–20; 8:45 am] I. Public Participation comprises an income statement with two schedules reconciling changes in BILLING CODE 6210–01–P A. Request for Comments capital and reserve accounts and a Interested parties are invited to balance sheet with 11 supporting participate in this activity by submitting VerDate Sep<11>2014 08:07 May 01, 2020 Jkt 250001 PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 E:\FR\FM\01MYN1.SGM 01MYN1 25440 Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices written views, opinions, medical school professor, a neurologist, • Does the draft policy and recommendations, and/or data. and an anonymous commenter. NIOSH procedures clearly describe the process Comments are invited on any topic also conducted a peer review, with four used by NIOSH to screen and evaluate related to the procedures and drugs independent reviewers, of the draft drugs? identified in this notice, including three Policy and Procedures.2 • Are the screening and evaluation draft documents: (1) NIOSH Procedures Significant peer review and public categorization processes described by for Developing the NIOSH List of comments on the draft Policy and the draft policy and procedures Hazardous Drugs in Healthcare Settings Procedures are summarized and scientifically sound? (Procedures); (2) NIOSH List of answered below in Section II; public • Is the set of information sources Hazardous Drugs in Healthcare Settings, comments on specific drugs are used for classifying drugs sufficient to 2020 (List), including those drugs summarized and answered below in identify relevant hazards? Are there identified in this notice as being Section III. other information sources that should be proposed for placement on the List; and NIOSH carefully considered all of the included? (3) Managing Hazardous Drug peer reviews and public comments and • Is the threshold of information Exposures: Information for Healthcare determined that significant, substantial required to move from the screening Settings. All three draft documents are changes should be made to the draft process to the full evaluation process available in the docket for this activity. Policy and Procedures, the list of drugs clearly described? Is the information NIOSH also invites comments proposed for placement on the List, and threshold scientifically sound? specifically on the following questions also to the organization of the List itself. • Is the reconsideration process for related to this activity: The new drafts, entitled the Procedures addition or deletion of a drug to/from 1. Which unique ingredient identifier for Developing the NIOSH List of the hazardous drug list adequately is the most useful for users of the List? Hazardous Drugs in Healthcare Settings described? • 2. Because there is conflicting (Procedures) and the NIOSH List of Are there any issues not considered evidence about the hazard posed by Hazardous Drugs in Healthcare Settings, by the charge questions that should be botulinum toxins to the workers who 2020 (List) are found in the addressed? handle these drugs, NIOSH is not Supplemental Materials tab of the Overall, the independent peer proposing the placement of botulinum docket and are available for public reviewers found the draft Policy